Covid-19 roundup: J&J and BAR­DA agree to $1 bil­lion for 100 mil­lion dos­es; Plas­ma re­duces mor­tal­i­ty by 50% — re­ports

J&J has be­come the lat­est vac­cine de­vel­op­er to agree to sup­ply BAR­DA with dos­es of their Covid-19 vac­cine, sign­ing an agree­ment that will give the gov­ern­ment 100 mil­lion dos­es in ex­change for $1 bil­lion in fund­ing.

The agree­ment, sim­i­lar to those signed by No­vavax, Sanofi and As­traZeneca-Ox­ford, pro­vides fund­ing not on­ly for in­di­vid­ual dos­es but to help J&J ramp up man­u­fac­tur­ing. Pfiz­er, by con­trast, re­ceived $1.95 bil­lion for the dos­es alone. Still, if one looked at each agree­ment as pur­chase amounts, J&J’s deal would be $10 per dose, slot­ting in be­tween No­vavax’s $16 per dose and As­traZeneca’s $4 per dose.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.